The current status of anti-obesity medication is that two drugs are licensed on the basis of moderate effi cacy in terms of weight loss and weight loss maintenance; their clinical development was based upon outdated regulatory requirements that distort the clinical perspectives for drug treatment. Future evaluation of anti-obesity drugs will need to address issues such as trial design to refl ect real-life practice, potential primary drug effects on co-morbidity, combination drug therapies, and predictors of individual response (including pharmacogenomics). It may become increasingly hard to justify long-term placebo-controlled treatment trials, while at the same time we need to explore the use of drugs earlier in the natural history of obesity development -i.e. at-risk adolescents and children. The rapid increase in our understanding of the physiology of weight regulation has led to a wide range of new and specifi c drug targets. The cannabinoid receptor antagonist rimonobant in Phase III clinical developments looks promising especially if data on desirable metabolic effects independent of weight loss are confi rmed. The atypical anticonvulsant topiramate produced excellent weight loss, but further trials are needed of new formulations designed to avoid unwanted CNS effects.
Plentiful targets that antagonise orexigenic or enhance anorectic pathways, both central and peripheral, are identifi ed, with many potential compounds in Phase I and II development. However, as the complexities of adipocyte's endocrine function unravel, drugs that modify its secretion may prove just as valuable as the ones that 'merely' alter energy balance.
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